Co-administration of CART22-65s and huCART19 for B-ALL

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

Trial Details

NCT ID

NCT05674175

Phase

PHASE1 / PHASE2

Sponsor

Stephan Grupp MD PhD

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

Locations (sample)

Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

Signed informed consent form
Patients with documented CD19+ and/or CD22+ ALL/LLy:
Cohort A: Patients with relapsed or refractory ALL/LLy:
Cohort B: Patients with poor response to prior B cell directed engineered cell therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →